Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a tissue sample
- People whose cancer has spread to the lining of the abdomen (the peritoneum), confirmed by both lab results and clinical assessment, with a spread score of at least 1
- People who are generally well enough to carry out daily activities (rated 0 or 1 on a standard health performance scale) and have a life expectancy of at least three months
- People aged 18 years or older
- People who have given written agreement to take part, following the required consent procedures
Who may not be able to join:
- People whose cancer has spread to parts of the body other than the abdominal lining or nearby lymph nodes
- People who have already received systemic (whole-body) drug treatment aimed at managing, rather than curing, their stomach cancer
- People who received pre- or post-surgery systemic treatment for stomach cancer within the six months before joining the study
- People who have severe fluid build-up in the abdomen that requires drainage at least once a month
- People who have a complete inherited deficiency of an enzyme called DPD, which affects how certain chemotherapy drugs are processed by the body
- People for whom the planned chemotherapy is not considered safe — for example, due to active infection, serious other illness, severe allergies, or lasting nerve damage from previous treatment — as determined by the treating cancer specialist
- People whose blood counts or organ function fall below certain levels, including low red blood cells, low white blood cells, low platelets, reduced kidney function, or elevated liver readings (confirm specific values with trial site)
- People who are pregnant or breastfeeding
- People already taking part in another clinical study that could affect the results of this trial
- People who are not expected to be able to follow the study requirements consistently
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pieter C van der Sluis, MD PhD, Erasmus MC, University Medical Center Rotterdam
Phone: 010 70 39640
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of intraperitoneal administration of irinotecan
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.